Canaccord Genuity analyst Whitney Ijem has maintained their bullish stance on GUTS stock, giving a Buy rating on May 13.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Whitney Ijem’s rating is based on several promising developments at Fractyl Health, Inc. The company has successfully completed the enrollment of its pivotal cohort in the REMAIN-1 study ahead of schedule, which indicates strong interest in their Revita product. This early completion is seen as a positive sign for future demand in the market.
Furthermore, the anticipated data from the midpoint analysis cohort in the REMAIN-1 study is expected to be available in the third quarter of 2025. If the results are favorable, it would significantly reduce the risk associated with the larger pivotal cohort data expected in the second half of 2026. Additionally, Fractyl Health ended the first quarter of 2025 with a solid cash position, which is projected to sustain operations into the fourth quarter of 2025. These factors contribute to the Buy rating with a price target of $12.
In another report released on May 13, Morgan Stanley also maintained a Buy rating on the stock with a $10.00 price target.
GUTS’s price has also changed moderately for the past six months – from $2.090 to $1.535, which is a -26.56% drop .